Portal de investigación
The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival
Autores organización
Autores
- Turcott, JG
- Martinez-Samano, JE
- Bassarmal, SS
- Ramírez-Tirado, LA
- Zatarain-Barrón, ZL
- Barron, F
- Corrales, L
- Martín, C
- Barragán-Castillo, PA
- Ruiz-Patiño, A
- Flores-Estrada, D
- Arrieta, O
Grupos de investigación
Resumen
Objective:The association between cancer-induced weight-loss (CIWL) and poor clinical outcomes in patients treated with immunotherapy is scarcely understood. We evaluated the use of a cachexia-grading system in IO-treated non-small cell lung cancer (NSCLC) patients in order to predict clinical outcomes. Materials:300 patients with NSCLC, who received immunotherapy during any line of therapy, were included. All patients were graded according to a previously validated cachexia scale, which takes into consideration body mass index (BMI) and weight loss, stratifying patients into five risk categories (0 [pre-cachexia] - 4 [refractory cachexia]). Primary endpoint was overall survival (OS). Results:Ninety-one (30.3%) patients were classified in the low risk category, 176 (58.6%) were classified in the intermediate risk category and 33 (11%) were in the high risk category. Patients classified as low-risk had a significantly longer OS compared with those with intermediate or high risk (22.4 mo, [95%CI: 16.6-NR]vs.17.1 [95%CI: 13.5-22.4] vs. 8.0 [3.9-18.4];p < 0.001). In the multivariate analysis, after adjusting for age, hemoglobin and ORR, hazard of death increased as per the cachexia risk scale (Hazard ratio: 1.62 [1.22-2.16];p = 0.001). Conclusion:Cachexia is independently associated with worse OS in NSCLC patients who receive immunotherapy, highlighting the role for nutritional assessment.
Datos de la publicación
- ISSN/ISSNe:
- 0163-5581, 1532-7914
- Tipo:
- Article
- Páginas:
- 794-801
- PubMed:
- 32482104
- Enlace a otro recurso:
- www.scopus.com
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL Routledge
Citas Recibidas en Web of Science: 5
Citas Recibidas en Scopus: 10
Documentos
- No hay documentos
Filiaciones
Keywords
- Cachexia; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Weight Loss; docetaxel; durvalumab; hemoglobin; ipilimumab; nivolumab; pembrolizumab; pemetrexed; ticilimumab; adult; age; Article; body mass; body weight loss; cachexia; cancer grading; cancer immunotherapy; cancer patient; cancer survival; clinical outcome; comparative study; evaluation study; female; health hazard; human; major clinical study; male; middle aged; multivariate analysis; non small cell lung cancer; overall survival; predictive value; retrospective study; risk assessment; cachexia; complication; immunotherapy; lung tumor